The FDA approves the first gene therapy for genetic hearing loss. The treatment is the sixth to receive authorization under the National Priority Voucher Program, following a 61-day review period.
The FDA has approved the first gene therapy for genetic hearing loss under the National Priority Voucher Program. This marks the sixth approval granted through the program, with the decision issued 61 days after filing.
What happened
The FDA has approved the first gene therapy for genetic hearing loss under the National Priority Voucher Program. This marks the sixth approval granted through the program, with the decision issued 61 days after filing.
Quick reaction
One tap helps tune what we surface next.
Reader discussion
Public commentsNo comments yet. Start the discussion around this signal.
Follow this signal
Get updates on this story
We will email you if this changes materially. No spam. Daily brief optional.
Map context
Open map near United States
Keep the story in context with nearby live signals, countries, and category movement.
Related coverage
More story pages
Trump aide pursued discredited Venezuela election-rigging theory, expanded probe to Georgia, Arizona — Reuters
A Trump aide continued pursuing the discredited theory that Venezuela rigged the 2020 U.S. presidential election, expanding the investigation to Georgia and Arizona despite finding no evidence, according to Reuters.
Virginia redistricting plan could give Democrats 4 new House seats, NBC News analysis shows
Virginia approved a redistricting plan that could help Democrats gain up to four additional congressional seats, according to an NBC News Decision Desk analysis of precinct data.
President Donald J. Trump announces a deal with Regeneron to secure most-favored-nation pricing for American patients, aiming to reduce healthcare costs.
President Donald J. Trump announced an agreement with Regeneron to implement most-favored-nation pricing for American patients.
SpaceX secures $20 billion short-term loan ahead of planned U.S. public listing, according to regulatory filings.
SpaceX has secured a $20 billion short-term loan ahead of a planned U.S. public listing, according to regulatory filings.
More live signals
Continue with the live feed.
The fastest nearby updates load from the public feed, not the enriched story endpoint.